Literature DB >> 30684555

Thrombospondin-1 Is a Major Activator of TGF-β Signaling in Recessive Dystrophic Epidermolysis Bullosa Fibroblasts.

Velina S Atanasova1, Rebecca J Russell1, Timothy G Webster1, Qingqing Cao1, Pooja Agarwal2, Yok Zuan Lim1, Suma Krishnan2, Ignacia Fuentes3, Christina Guttmann-Gruber4, John A McGrath5, Julio C Salas-Alanis6, Andrzej Fertala7, Andrew P South8.   

Abstract

Mutations in the gene encoding collagen VII cause the devastating blistering disease recessive dystrophic epidermolysis bullosa (RDEB). RDEB is characterized by severe skin fragility and nonhealing wounds aggravated by scarring and fibrosis. We previously showed that TSP1 is increased in RDEB fibroblasts. Because transforming growth factor-β (TGF-β) signaling is also increased in RDEB, and TSP1 is known to activate TGF-β, we investigated the role of TSP1 in TGF-β signaling in RDEB patient cells. Knockdown of TSP1 reduced phosphorylation of smad3 (a downstream target of TGF-β signaling) in RDEB primary fibroblasts, whereas overexpression of collagen VII reduced phosphorylation of smad3. Furthermore, inhibition of TSP1 binding to the LAP/TGF-β complex decreased fibrosis in engineered extracellular matrix formed by RDEB fibroblasts, as evaluated by picrosirius red staining and analyses of birefringent collagen fibrillar deposits. We show that collagen VII binds TSP1, which could potentially limit TSP1-LAP association and subsequent TGF-β activation. Our study suggests a previously unreported mechanism for increased TGF-β signaling in the absence of collagen VII in RDEB patient skin. Moreover, these data identify TSP1 as a possible target for reducing fibrosis in the tumor-promoting dermal microenvironment of RDEB patients.
Copyright © 2019 The Authors. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 30684555     DOI: 10.1016/j.jid.2019.01.011

Source DB:  PubMed          Journal:  J Invest Dermatol        ISSN: 0022-202X            Impact factor:   8.551


  12 in total

1.  Molecular alterations due to Col5a1 haploinsufficiency in a mouse model of classic Ehlers-Danlos syndrome.

Authors:  Keren Machol; Urszula Polak; Monika Weisz-Hubshman; I-Wen Song; Shan Chen; Ming-Ming Jiang; Yuqing Chen-Evenson; Mary Ann E Weis; Douglas R Keene; David R Eyre; Brendan H Lee
Journal:  Hum Mol Genet       Date:  2022-04-22       Impact factor: 5.121

Review 2.  Emerging role of tumor cell plasticity in modifying therapeutic response.

Authors:  Siyuan Qin; Jingwen Jiang; Yi Lu; Edouard C Nice; Canhua Huang; Jian Zhang; Weifeng He
Journal:  Signal Transduct Target Ther       Date:  2020-10-07

Review 3.  Molecular Therapeutics in Development for Epidermolysis Bullosa: Update 2020.

Authors:  Cristina Has; Andrew South; Jouni Uitto
Journal:  Mol Diagn Ther       Date:  2020-06       Impact factor: 4.074

4.  Role of TSP-1 as prognostic marker in various cancers: a systematic review and meta-analysis.

Authors:  Shengjie Sun; Huiyu Dong; Tao Yan; Junchen Li; Bianjiang Liu; Pengfei Shao; Jie Li; Chao Liang
Journal:  BMC Med Genet       Date:  2020-06-29       Impact factor: 2.103

Review 5.  Epidermolysis Bullosa-Associated Squamous Cell Carcinoma: From Pathogenesis to Therapeutic Perspectives.

Authors:  Angelo Giuseppe Condorelli; Elena Dellambra; Elena Logli; Giovanna Zambruno; Daniele Castiglia
Journal:  Int J Mol Sci       Date:  2019-11-14       Impact factor: 5.923

Review 6.  Small molecule drug development for rare genodermatoses - evaluation of the current status in epidermolysis bullosa.

Authors:  Verena Wally; Manuela Reisenberger; Sophie Kitzmüller; Martin Laimer
Journal:  Orphanet J Rare Dis       Date:  2020-10-19       Impact factor: 4.123

7.  Signatures of Dermal Fibroblasts from RDEB Pediatric Patients.

Authors:  Arkadii K Beilin; Nadezhda A Evtushenko; Daniil K Lukyanov; Nikolay N Murashkin; Eduard T Ambarchian; Alexander A Pushkov; Kirill V Savostyanov; Andrey P Fisenko; Olga S Rogovaya; Andrey V Vasiliev; Ekaterina A Vorotelyak; Nadya G Gurskaya
Journal:  Int J Mol Sci       Date:  2021-02-11       Impact factor: 5.923

Review 8.  A Review of Acquired Autoimmune Blistering Diseases in Inherited Epidermolysis Bullosa: Implications for the Future of Gene Therapy.

Authors:  Payal M Patel; Virginia A Jones; Christy T Behnam; Giovanni Di Zenzo; Kyle T Amber
Journal:  Antibodies (Basel)       Date:  2021-05-17

Review 9.  Impaired Wound Healing, Fibrosis, and Cancer: The Paradigm of Recessive Dystrophic Epidermolysis Bullosa.

Authors:  Grace Tartaglia; Qingqing Cao; Zachary M Padron; Andrew P South
Journal:  Int J Mol Sci       Date:  2021-05-12       Impact factor: 5.923

10.  Translational perspectives to treat Epidermolysis bullosa-Where do we stand?

Authors:  Christine Prodinger; Johann W Bauer; Martin Laimer
Journal:  Exp Dermatol       Date:  2020-11       Impact factor: 4.511

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.